COVID-19. Covid-19
Conditions
Interventions
Intervention 1: Intervention group: Guluronic acid (G2013) capsule 500 mg, 2 capsules every 12 hours, after meal, for 4 weeks
in addition to routine treatment according to the latest national guideline. Intervention 2: Control group: routine treatment according to the latest national guideline.
Sponsors
Ministry of Defense, Department of Health
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Confirmed diagnosis of COVID-19, with either lung CT-Scan result, which is typical for COVID-19 pulmonary involvement,or RT-PCR confirmation. The patient/Legal guardian has written consciously and freely consent to participate in the study; In the first 48 hours after his/her inclusion into this study, there is no possibility of discharge from the patient's hospital; Moderate to severe COVID pneumonia
Exclusion criteria
Exclusion criteria: Pregnancy Lactation The patient is present at another clinical trial at the same time. Severe renal impairment Severe hepatic impairment Severe cardiac impairment Uncontrolled diabetes Active infection Active cancer Coagulopathy Primary immunodeficiency syndrome Allergy to Glurunic acid
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Need to receive ICU service rate (occurrence of shock, resistant hypoxemia despite receiving oxygen via reservoir oxygen mask, GCS score drops below 12). Timepoint: Daily. Method of measurement: Clinical assessment. | — |
Secondary
| Measure | Time frame |
|---|---|
| Mortality rate. Timepoint: 30 days after including the study. Method of measurement: Clinical assessment.;Length of hospitalization. Timepoint: The first day and the end of hospitalization. Method of measurement: The hospital record review.;Laboratory changes. Timepoint: Daily until discharge. Method of measurement: Blood sample, laboratory analysis.;Fever. Timepoint: Daily until discharge. Method of measurement: Clinical assessment.;Respiratory distress. Timepoint: Daily until discharge. Method of measurement: Clinical assessment.;Oxygen saturation without receiving oxygen supplement. Timepoint: Daily until discharge. Method of measurement: Pulse-oxymetery device.;Side effects. Timepoint: Daily during hospitalization, weekly after discharge. Method of measurement: During hospitalization by clinical evaluation, after discharge by telephone follow-up. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactArmita Mahdavi Goorabi
Shahid Dr. Chamran hospital
Outcome results
None listed